Looking Out for Side Effects in Immunotherapy Combination Treatment

Video

Immunotherapy in combination with chemotherapy is becoming a popular treatment for patients with lung cancer, but patients need to understand the side effects.

Immunotherapy in combination with chemotherapy brings on more side effects during treatment, however, serious side effects in combination treatment remain similar to side effects in chemotherapy alone, according to Nagashree Seetharamu, MD, MBBS.

At the CURE® Patient-Focused Sessions at the New York Lung Cancers Symposium® Seetharamu, associate professor in Clinical Medicine at Hofstra and Northwell Health, presented on the benefits and challenges for immunotherapy and chemotherapy combination treatment for patients with lung cancer. Seethearamu also sat with CURE to discuss the side effect realities of this combination treatment and why patients must remain vigilant as they undergo the combination therapy.

TRANSCRIPTION

You have immunotherapy with its own set of side effects. They're not overlapping, meaning that they don't cause the same type of side effects, for the most part, the immunotherapy causes side effects by an overactive immune system. When the immune cells that we are trying to activate or trying to get stronger to attack the cancer cells, may sometimes attack one's own body, that's where the side effects come.

When you do the two together, the side effects are numerically more, but the serious side effects are not that very different in the two groups, patients receiving chemotherapy alone versus patients receiving chemotherapy plus immunotherapy.

The one message I give to patients on immunotherapy, whether by itself or in combination with chemotherapy, is to make a note of anything that is not normal for them from the time they start the treatment. If there is anything new that happens, I don't want them to be guessing whether is it a side effect? Or is it something that I ate yesterday? I would not want them to guess, I want them to give the information to me and let me do the guessing because these side effects with immunotherapy are reversible if it's tackled in a timely fashion.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE